RxDoctor Payments Data

Vivian Dudley

Nurse Practitioner · Bourbon, MONPI 1013018654

Payments from drug & device makers

$2,082in general payments, 2019–2025

Across 106 payments — averaging $19.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Astellas Pharma US Inc$99
  • Lilly USA, LLC$28
  • Novo Nordisk$16
  • GSK$14
  • Amgen$14

What the payments were for

  • Food & beverage$1,95594%
  • Education$1276%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie100$1,912
Astellas Pharma US Inc1$99
Lilly USA, LLC2$28
Novo Nordisk1$16
GSK1$14
Amgen1$14

How this compares

$2,082 in reported general payments places this provider in the 85th percentile of 1,898 nurse practitioner providers in Missouri.

See all nurse practitioner providers in Missouri

Medicare billing

Part B allowed, 2024
$1,437
Medicare patients
41
Services billed
63

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin180$139,138
Trelegy ElliptaFluticasone/Umeclidin/Vilanter171$130,640
MounjaroTirzepatide89$112,103
OzempicSemaglutide98$102,130
TrulicityDulaglutide51$58,304
XareltoRivaroxaban53$50,689
Soliqua 100-33Insulin Glargine/Lixisenatide44$46,272
NucalaMepolizumab13$44,811
XifaxanRifaximin13$41,576
Abilify MaintenaAripiprazole13$38,169
LinzessLinaclotide52$35,187
EliquisApixaban70$33,626
MyrbetriqMirabegron53$29,224
RybelsusSemaglutide19$26,104
FarxigaDapagliflozin Propanediol28$22,740

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Arexvy$14$195,007236 claims
Lilly USA, LLCMounjaro, Trulicity$28$170,407140 claims
Novo NordiskOzempic, Rybelsus, Wegovy$16$145,525130 claims
AbbVieLinzess$1,912$35,18752 claims
Astellas Pharma US IncMyrbetriq$99$29,22453 claims
AmgenProlia$14$18,84211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,898 nurse practitioner providers in Missouri.

Other nurse practitioner in Bourbon

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →